Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
pharmaceuticals: Archive
Top Stock Reports for Broadcom, Merck & Airbnb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
PCGPositive Net Change MRKPositive Net Change OKENegative Net Change ENBNo Net Change AVGOPositive Net Change ABNBNegative Net Change
internet-content pharmaceuticals semiconductor
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
by Zacks Equity Research
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
by Zacks Equity Research
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
pharmaceuticals
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
by Zacks Equity Research
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
UTHRPositive Net Change LGNDPositive Net Change ANIPNegative Net Change ALLOPositive Net Change
biotechs cell-therapy earnings medical pharmaceuticals
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
by Zacks Equity Research
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
ABBVPositive Net Change CEREPositive Net Change THRDPositive Net Change
pharmaceuticals
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
by Zacks Equity Research
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
NVOPositive Net Change LGNDPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
by Zacks Equity Research
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
MRKPositive Net Change MRNAPositive Net Change LGNDPositive Net Change ANIPNegative Net Change
pharmaceuticals
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
by Zacks Equity Research
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
REGNNegative Net Change JNJPositive Net Change BAYRYPositive Net Change LGNDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
AZNNegative Net Change BMYNegative Net Change MRKPositive Net Change LGNDPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
by Zacks Equity Research
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
REGNNegative Net Change SNYNegative Net Change LGNDPositive Net Change ANIPNegative Net Change
pharmaceuticals
Bull of the Day: Veeva Systems (VEEV)
by Benjamin Rains
The tech firm and the stock are proven winners. Now might be the time for investors to heed tried-and-true investment advice and buy Veeva while others are fearful.
VEEVPositive Net Change
biotechnology pharmaceuticals tech-stocks
Top Stock Reports for Amazon.com, Visa & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE).
AMZNNegative Net Change VPositive Net Change PFEPositive Net Change MLMPositive Net Change TRPPositive Net Change ZBHPositive Net Change
business-services pharmaceuticals retail
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
by Zacks Equity Research
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
VRTXPositive Net Change HTGCNegative Net Change BLUENo Net Change CRSPPositive Net Change
biotechs earnings gene-therapy pharmaceuticals
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
by Kinjel Shah
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
LGNDPositive Net Change FOLDPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXPositive Net Change ANIPNegative Net Change XENENegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
3 Stocks to Buy Following Guidance Upgrades
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture. And that's precisely what these three companies have recently announced.
LLYPositive Net Change ETNPositive Net Change ANETPositive Net Change
artificial-intelligence electronics medical pharmaceuticals tech-stocks
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
by Zacks Equity Research
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
JNJPositive Net Change TEVANegative Net Change LGNDPositive Net Change ABBVPositive Net Change
pharmaceuticals
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
RHHBYPositive Net Change BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
LGNDPositive Net Change CPRXPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
by Zacks Equity Research
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
LGNDPositive Net Change ANIPNegative Net Change BBIOPositive Net Change VTRSNegative Net Change
earnings medical pharmaceuticals
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
VRTXPositive Net Change UTHRPositive Net Change LGNDPositive Net Change CRSPPositive Net Change
biotechs cell-therapy crispr earnings gene-editing gene-therapy immuno-therapy medical pharmaceuticals
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
LGNDPositive Net Change ANIPNegative Net Change ACADPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
LGNDPositive Net Change ANIPNegative Net Change ITCIPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
LGNDPositive Net Change PCRXNegative Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals